Imeglimin: a new antidiabetic drug with potential future in the treatment of patients with type 2 diabetes

Nowak, Mariusz; Grzeszczak, Władysław

doi:10.5603/ep.a2022.0014

Cited by 11 publications

(3 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although IMEG exerts similar effects to those of metformin on AMPK activity, it is yet to be determined whether it is potent enough to phase-shift the circadian rhythms [ 120 ]. IMEG is currently administered twice daily, in the morning and evening [ 121 ], but further studies are needed to determine whether IMEG’s effects depend on the time of day it is administered.…”

Section: Treatment Of Mets In Alignment With Circadian Rhythmmentioning

confidence: 99%

Timing Is Important—Management of Metabolic Syndrome According to the Circadian Rhythm

et al. 2023

View full text Add to dashboard Cite

Physiological processes occur in accordance with a rhythm regulated by the endogenous biological clock. This clock is programmed at the molecular level and synchronized with the daily light–dark cycle, as well as activities such as feeding, exercise, and social interactions. It consists of the core clock genes, Circadian Locomotor Output Cycles Protein Kaput (CLOCK) and Brain and Muscle Arnt-Like protein 1 (BMAL1), and their products, the period (PER) and cryptochrome (CRY) proteins, as well as an interlocked feedback loop which includes reverse-strand avian erythroblastic leukemia (ERBA) oncogene receptors (REV-ERBs) and retinoic acid-related orphan receptors (RORs). These genes are involved in the regulation of metabolic pathways and hormone release. Therefore, circadian rhythm disruption leads to development of metabolic syndrome (MetS). MetS refers to a cluster of risk factors (RFs), which are not only associated with the development of cardiovascular (CV) disease (CVD), but also with increased all-cause mortality. In this review, we consider the importance of the circadian rhythm in the regulation of metabolic processes, the significance of circadian misalignment in the pathogenesis of MetS, and the management of MetS in relation to the cellular molecular clock.

show abstract

Section: Treatment Of Mets In Alignment With Circadian Rhythmmentioning

confidence: 99%

Timing Is Important—Management of Metabolic Syndrome According to the Circadian Rhythm

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Our paper appears to suggest that IMEG, with its novel mechanism of action, has the opportunity to improve outcomes for many T2DM patients. [33] 32. Sathawane et al 2023 imeglimin hydrochloride is used in the treatment of type 2 diabetes.…”

mentioning

confidence: 99%

Imeglimin Hydrochloride: A Novel Approach to Type 2 Diabetes Management

Sharma,

Sethi,

Dalal

et al. 2024

jaz

View full text Add to dashboard Cite

Imeglimin hydrochloride is an novel drug evolve for the treatment of type 2 diabetes mellitus. It is characterized by its unique mechanism of action, targeting both pancreatic beta cells and peripheral tissues to improve insulin secretion and sensitivity. Early clinical trials showed promise in reducing blood sugar levels, but further research was needed to determine its safety and effectiveness. Some reported side effects included gastrointestinal symptoms like nausea and diarrhea. The regulatory status of Imeglimin varied by region, and patients were advised to consult with healthcare professionals for the latest information on its availability and use. Validation of imeglimin hydrochloride and its enantiomers, drug release patterns of the nanofibers, comparing its impact with other available drug like metformin, method of action by targeting mitrocondria, pharmacokinetics and therapeutic effect of imeglimin hydrochloride, Imeglimin treatment, both short-and long-term, counteracts the metabolic syndrome's cardiorenal dysfunction, its Potential Ketoacidosis, its solubility and UV-Spectrophotometry. [1] INTRODUCTION:A novel molecule called imeglimin is being developed to treat type 2 diabetes. This medication belongs to the glimin class of glucose-lowering medications, making it the first of its kind in this category. Optimal glucose regulation is necessary in type 2 diabetes to correct anomalies in insulin responsiveness and release. Imeglimin operates through a distinctive mechanism of action, addressing three crucial pathophysiological aspects of type 2 diabetes: greater death of cells, increased hypergluconeogenesis, and decreased muscle tissue absorption of glucose. Recent stage II and phase III studies revealed imeglimin's efficacy for enhancing the level of glycated haemoglobin and fasting blood glucose (FPG) levels, either alone or in conjunction with other sugar-lowering medications. The rise of diabetes type 2 mellitus (T2DM) in the twenty-first century poses a serious medical, societal, and economic problem. The number of individuals with carbohydrate metabolism problems is growing, particularly among young people. By following the World Diabetes Federation (IDF), The global diabetic population is projected to rise from 463 million in 2019 to reach 700 million by the year 2045. T2DM is typically detected 10 years after the disease manifests itself, and a considerable proportion of people with it already have serious micro-and/or macroangiopathy consequences at the time of diagnosis. Diabetes

show abstract

“…

intensively studied in clinical trials, showing not only hypoglycaemic effects but also influencing the comorbid metabolic components of the disease. These include the following: 1 -activin type II receptor modulators (bimagrumab), 2 -amylin or dual amylin-calcitonin receptor agonists (Pramlintide-amylin agonist), 3 -activator of adenosine monophosphate-activated protein kinase (AMPK) (A-769,662, thienopyridone), 4 -analogues of fibroblast growth factor 21 (pegbelfermin), 5 -fructose-1,6-bisphosphatase inhibitors (VK0612; MB07803), 6 -new GLP-1 receptor agonists (albiglutide, dulaglutide, exenatide, liraglutide, lyxisenatide, semaglutide, efpeglenatide, glutazumab, ITCA-650), 7 -drugs affecting the activity of the sodium-glucose cotransporter (SGLT 1 and 2) (SGLT 1 -licogliflozin, sotagliflozin and LX2761; SGLT 2 -kanagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, remogliflozin and tofogliflozin), or 8 -imeglimin belonging to a new group of drugs, so-called glimin [1,2].

…”

mentioning

confidence: 99%

Tirzepatide — a dual GIP/GLP-1 receptor agonist — a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes

Nowak

Grzeszczak³

2022

Endokrynol Pol

Self Cite

View full text Add to dashboard Cite

show abstract

Imeglimin: a new antidiabetic drug with potential future in the treatment of patients with type 2 diabetes

Cited by 11 publications

References 49 publications

Timing Is Important—Management of Metabolic Syndrome According to the Circadian Rhythm

Timing Is Important—Management of Metabolic Syndrome According to the Circadian Rhythm

Imeglimin Hydrochloride: A Novel Approach to Type 2 Diabetes Management

Tirzepatide — a dual GIP/GLP-1 receptor agonist — a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes

Contact Info

Product

Resources

About